New clinical data for Medivir AB’s once-daily HCV protease inhibitor simeprevir were presented at the 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Istanbul, Turkey, recently. Six oral and poster presentations were held on three clinical studies involving several development programs including simeprevir in different treatment combinations, durations and populations, according to Cision.
The combination treatments in all of the panels generally were well tolerated.
“We have a long and fruitful relationship with our global partner Janssen on simeprevir. These data show the commitment Janssen has for the HCV area, with studies of simeprevir in a wide range of patient populations and treatment regimens,” says Niklas Prager, Medivir’s CEO.
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen Sciences Ireland UC and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis.
In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it has so far been made available in several EU countries in conjunction with reimbursement.